# A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

> **NCT04718675** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kronos Bio** · enrollment: 135 (actual)

## Conditions studied

- Relapsed Solid Tumors
- Refractory Solid Tumors
- Non-Hodgkin Lymphoma
- HGSOC
- Platinum Resistant High Grade Serous Ovarian Cancer

## Interventions

- **DRUG:** KB-0742

## Key facts

- **NCT ID:** NCT04718675
- **Lead sponsor:** Kronos Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-08
- **Primary completion:** 2025-01-07
- **Final completion:** 2025-02-07
- **Target enrollment:** 135 (ACTUAL)
- **Why stopped:** Due to lack of safety and futility
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718675, "A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04718675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*